Olio Labs
Olio Labs designs combination therapies that aim to deliver better health outcomes with fewer side effects. Their platform utilizes AI to develop therapeutics that consider the complex interactions within the body, focusing on the development of combination treatments for challenging diseases.
Industries
Nr. of Employees
small (1-50)
Olio Labs
California City, California, United States, North America
Products
Computational platform for designing combination therapies
A software-driven platform that integrates machine learning and systems biology models to propose multi-agent therapeutic combinations and analyze their predicted effects.
Computational platform for designing combination therapies
A software-driven platform that integrates machine learning and systems biology models to propose multi-agent therapeutic combinations and analyze their predicted effects.
Services
Advisory support for clinical trial protocol design and trial-related translational questions.
Collaborative access to computational methods and engineering support for designing and evaluating multi-drug combinations.
Advisory support for clinical trial protocol design and trial-related translational questions.
Collaborative access to computational methods and engineering support for designing and evaluating multi-drug combinations.
Expertise Areas
- Combination therapeutics design
- AI/ML for drug discovery
- Systems biology and network modeling
- Preclinical experimental research
Key Technologies
- Machine learning for therapeutics
- Computational modeling of protein interaction networks
- Drug combination prediction algorithms
- Preclinical laboratory assays
News & Updates
Olio Labs identifies why women experience stronger side effects from GLP-1 drugs, as detailed in a study published on March 18, 2025.
Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two, as reported on August 4th, 2023.
Olio Labs identifies why women experience stronger side effects from GLP-1 drugs, as detailed in a study published on March 18, 2025.
Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two, as reported on August 4th, 2023.